Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Novel Research in Sciences

Abnormal Methylation Enzymes as the Bullseye of Targeted Cancer Therapies

Submission: April 16, 2021;Published: May 3, 2021

Abstract

Non-targeted cell killing is the choice of cancer therapy in the past, because it is the most effective strategy to stop the perpetual proliferation of cancer cells. Non-targeted cell killing includes cytotoxic chemotherapy and radiotherapy that aims to kill cells in replication indiscriminately. Non-targeted cell killing dominates cancer therapy for as long as one can remember, but cancer mortalities remain at old time high worldwide. Obviously, non-targeted cell killing is unable to save the majority of cancer patients.

Get access to the full text of this article